Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals Inc. (VRTX)
:VRTX
VRTX Stock Chart & Stats
$429.22
$0.48(0.12%)
At close: 4:00 PM EST
$429.22
$0.48(0.12%)
Day’s Range― - ―
52-Week Range$362.50 - $519.68
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.44M
Market Cap
$103.89B
Enterprise Value$96.43B
Total Cash (Recent Filing)$6.29B
Total Debt (Recent Filing)$1.83B
Price to Earnings (P/E)29.7
Beta0.61
Next Earnings
Feb 04, 2026EPS Estimate
5.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.80
Shares Outstanding253,718,830
10 Day Avg. Volume1,495,319
30 Day Avg. Volume1,439,384
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)6.32
Price to Sales (P/S)9.41
P/FCF Ratio-131.21
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue8.23
Enterprise Value/Gross Profit9.53
Enterprise Value/Ebitda20.69
Forecast
1Y Price Target
$481.64Price Target Upside12.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessVertex's renal programs are emerging as the company's next major growth driver, building on the success of its cystic fibrosis franchise.
Financial PerformanceVertex reported 3Q25 results with revenue of $3.08B, up 11% y/y, above consensus of $3.06B, and non-GAAP EPS of $4.80 above consensus of $4.58.
Regulatory MomentumThe rolling BLA review for IgAN underscores regulatory momentum, suggesting progress in Vertex's kidney franchise.
Bears Say
Commercial ChallengesDespite the growth in the therapeutic landscape of IgAN, the slow penetration of currently approved drugs means Vertex might have some work to do at the commercial front.
Safety And Efficacy QuestionsPovetacicept showed a consistent safety profile to other BAFF/APRIL inhibitors but with consideration for infection risk in 43% of IgAN patients at the 80 mg dose.
Valuation ConcernsVertex shares currently trade at a P/E multiple of 20.5x 2026E consensus EPS vs. the mega-cap BioPharma peer average of 14.0x, leading to a Hold rating.
Vertex Pharmaceuticals News
VRTX FAQ
What was Vertex Pharmaceuticals Inc.’s price range in the past 12 months?
Vertex Pharmaceuticals Inc. lowest stock price was $362.50 and its highest was $519.68 in the past 12 months.
What is Vertex Pharmaceuticals Inc.’s market cap?
Vertex Pharmaceuticals Inc.’s market cap is $103.89B.
When is Vertex Pharmaceuticals Inc.’s upcoming earnings report date?
Vertex Pharmaceuticals Inc.’s upcoming earnings report date is Feb 04, 2026 which is in 84 days.
How were Vertex Pharmaceuticals Inc.’s earnings last quarter?
Vertex Pharmaceuticals Inc. released its earnings results on Nov 03, 2025. The company reported $4.8 earnings per share for the quarter, beating the consensus estimate of $4.573 by $0.227.
Is Vertex Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vertex Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vertex Pharmaceuticals Inc. pay dividends?
Vertex Pharmaceuticals Inc. does not currently pay dividends.
What is Vertex Pharmaceuticals Inc.’s EPS estimate?
Vertex Pharmaceuticals Inc.’s EPS estimate is 5.13.
How many shares outstanding does Vertex Pharmaceuticals Inc. have?
Vertex Pharmaceuticals Inc. has 253,718,830 shares outstanding.
What happened to Vertex Pharmaceuticals Inc.’s price movement after its last earnings report?
Vertex Pharmaceuticals Inc. reported an EPS of $4.8 in its last earnings report, beating expectations of $4.573. Following the earnings report the stock price went up 0.101%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VRTX
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$481.64 (12.21% Upside)
$481.64 (12.21% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 67.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.45%
12-Months-Change
Fundamentals
Return on Equity
22.31%
Trailing 12-Months
Asset Growth
11.79%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. The company primarily operates in the fields of cystic fibrosis (CF) and other serious diseases, leveraging its expertise in genetics and drug development to create transformative therapies. Vertex is best known for its portfolio of CF treatments, including Kalydeco, Orkambi, and Trikafta, which target the underlying causes of the disease rather than just its symptoms.
VRTX Company Deck
VRTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, significant revenue growth across multiple products, and promising pipeline advancements, particularly in the renal and CF segments. However, challenges remain with high gross to net impacts and some regulatory and development delays.View all VRTX earnings summariesVRTX Revenue Breakdown
92.91% TRIKAFTA/KAFTRIO
7.09% Other product revenues
VRTX Stock 12 Month Forecast
Average Price Target
$481.64
▲(12.21% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
38.33% Mutual Funds
0.50% Other Institutional Investors
34.67% Public Companies and Individual Investors